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Abstract
Primary myofibroblastic sarcoma is an extremely rare, highly malignant neoplasm, and only few cases had been
reported in the literature worldwide. In the present study, we report an unusual case of a low-grade myofibroblastic
sarcoma located in the posterior chest wall with intrathoracic propagation and discuss its clinical and pathological
features.
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To the Editor,
Myofibroblastic sarcoma (MS) is considered as an ex-
tremely rare entity of soft tissue neoplasms, defined
as a malignant neoplastic myofibroblastic proliferation
with fibromatosis-like features [1]. It has been known
to arise mainly at the head and neck regions, al-
though it could be rarely found at the extremities and
trunk, and thus, only a small number of cases have
been reported in the literature worldwide [1, 2].
Treatment primarily involves surgical resection while
the role of adjuvant or palliative radio-chemotherapy
remains unclear [2]. We would like to draw attention
to a case of low-grade myofibroblastic sarcoma
(LGMS) occurring in the posterior chest wall of a
41-year-old man and discuss its clinical, radiological
and microscopical features.
A 41-year-old man was referred for the manage-
ment of painful bleeding and swelling in the area of
the left scapula (Fig. 1). A giant bleeding tumour,
29 × 22 cm in size, had been growing insidiously for
the preceding 2 months before hospital admission
(Fig. 2). The mass was surgically removed with early
relapse within several months. The histopathology
examination showed malignant SMA+, Desmin−,
CD99+, S100+/ALK−, and CD34− sarcoma cells with
nuclear hyperchromasia and mild cellular pleo-
morphism. The histological features were compatible
with a very rare entity—the LGMS (Fig. 3). The find-
ings of further metastatic workups were positive.
The patient received adjuvant chemotherapy (6×
MAID and 2× ICE regimen) with significant clinical
improvement, and 6 months progression-free survival
was achieved.
MS is a rare infiltrative low- or high-grade mesen-
chymal tumour that arises usually in a soft tissue
with a predilection for the head and neck region.
Other locations on the body are extremely rare [1, 2].
While MS has indolent course, in our case, the
disease presentation were very specific with the pain
and tumour growth in the region involved. The radio-
logical features of MS have not been well documented
because of its rareness. Nevertheless, computed tom-
ography, magnetic resonance imaging and positron
emission tomography are effective methods in detect-
ing the tumour, esspecially by developing in the
thoracic or abdominal cavity [3]. The exact diagnosis
of MS relies on pathological findings [3–5]. The diag-
nosis must be differentiated from malignant fibrous
histiocytoma, leiomyosarcoma, inflammatory myofi-
broblastic tumour and other various reactive condi-
tions or benign tumours. Histopathologically and
immunohistochemically, LGMS is composed of slen-
der spindle cells with vesicular nuclei showing immu-
nopositivity for CD99, vimentin and SMA, while
desmin and ALK are mostly immunonegative [3–5].
The electron microscopy as well as cytogenetic and
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molecular genetic alterations of the tumours are
presently obscure, and they need to be reviewed in the
future. Clinically, LGMS is an aggressive neoplasm with
frequent recurrence rate and high metastatic potential and
should be treated by surgicaly excision. The surgery
should be performed by an experienced surgeon with
preserving the function of blood vessels, muscles and
nerves where possible. Evaluation of the resectability of a
LGMS depends on the tumour stage and the patient’s
co-morbidity. The growth pattern of the cancer requires
that a wide margin of normal tissues be removed with
tumour debulking. This requirement, due to the anatom-
ical condsiderations, must determine the type of oper-
ation. An acceptable margin of normal tissue is commonly
accepted as 1 cm soft tissue. If wide resection is not
possible, it may be acceptable to leave microscopic-
positive surgical margins but this cases require adjuvant
treament with radio-chemotherapy [6]. Only under these
conditions, a favourable prognosis may be attained. The
therapeutic effects of adjuvant chemotherapy or radiation
therapy are still unclear [1, 2]. Our patient was treated
with MAID and ICE regimen, and we were able to achive
a 6-month progression-free survival. Preoperative diagno-
sis is based on clinical examination, imaging techniques
and biopsy of suspected lesion as well as intraoperative
histological diagnosis. The standard medical follow-up
must include clinical examination to focus on local
recurrence and radiological evaluation where indicated by
Fig. 1 Clinical picture of the exulcerated bleeding myofibrosrcoma of the posterior chest wall
Fig. 2 Computed tomography imaging of the chest showing giant tumor mass measuring 29 × 22 cm in size with destruction of the chest wall
and propagation in to the chest cavity
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clinical suspicion. Finally, the main clinical challenge
remains prevention of local recurrence or metastatic
spreading. Therefore, periodic imaging examinations and
regular medical lifelong follow-up is mandatory [6].
Abbrevations
ALK: Anaplastic lymphoma kinase; CD34: Cluster of differentiation 34;
CD99: Cluster of differentiation 99; ICE: Ifosfamide, carboplatine, etoposide;
LGMS: Low-grade myofibroblastic sarcoma; MAID: Mesna, doxorubicin,
ifosfamid, dacarbazine; MS: Myofibroblastic sarcoma; S100: S100 protein;
SMA: Smooth muscle actin
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Fig. 3 Histopathological analysis showing spindle-shaped tumour cells arranged in interlacing fascicles or storiform pattern with scattered necrosis
and haemorrhage (a–b; HE staging, original magnification ×400). The tumour cells were positive for SMA and CD99 and negative for desmin and
CD34, all consistent with low-grade myofibrosarcoma (c–d; immunohistochemical staging, original magnification ×400)
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